Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G G Steger

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Anti-Cancer Drugs|April 6, 2001
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patientsG J Locker, C Wenzel, M Schmidinger, et al.
Oncology|March 1, 1995
New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancerG J Locker, R M Mader, J Braun, et al.
British Journal of Clinical Pharmacology|March 1, 1994
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancerR M Mader, G G Steger, B Rizovski, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administrationG G Steger, R M Mader, M P Djavanmard, et al.
British Journal of Cancer|March 6, 2003
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancerR M Mader, C Schrolnberger, B Rizovski, et al.
Biochemical Pharmacology|January 7, 1998
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitroR M Mader, A E Sieder, J Braun, et al.
Leukemia|November 1, 1994
Karyotype and prognosis in non-Hodgkin lymphomaH Pirc-Danoewinata, A Chott, E Onderka, et al.
Cancer Research|July 29, 1998
Interstitial methotrexate kinetics in primary breast cancer lesionsM Müller, M Brunner, R Schmid, et al.
Anti-Cancer Drugs|June 1, 2000
Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinomaM Schmidinger, G G Steger, A C Budinsky, et al.
The Journal of Laboratory and Clinical Medicine|June 1, 2001
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNAR M Mader, W M Schmidt, R Sedivy, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Anti-Cancer Drugs|April 6, 2001
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patientsG J Locker, C Wenzel, M Schmidinger, et al.
Oncology|March 1, 1995
New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancerG J Locker, R M Mader, J Braun, et al.
British Journal of Clinical Pharmacology|March 1, 1994
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancerR M Mader, G G Steger, B Rizovski, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administrationG G Steger, R M Mader, M P Djavanmard, et al.
British Journal of Cancer|March 6, 2003
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancerR M Mader, C Schrolnberger, B Rizovski, et al.
Biochemical Pharmacology|January 7, 1998
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitroR M Mader, A E Sieder, J Braun, et al.
Leukemia|November 1, 1994
Karyotype and prognosis in non-Hodgkin lymphomaH Pirc-Danoewinata, A Chott, E Onderka, et al.
Cancer Research|July 29, 1998
Interstitial methotrexate kinetics in primary breast cancer lesionsM Müller, M Brunner, R Schmid, et al.
Anti-Cancer Drugs|June 1, 2000
Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinomaM Schmidinger, G G Steger, A C Budinsky, et al.
The Journal of Laboratory and Clinical Medicine|June 1, 2001
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNAR M Mader, W M Schmidt, R Sedivy, et al.
Pageof 7